Holen Sie sich die Stockscreener-App
71.19
1.59%
-1.15
Handel nachbörslich:
71.19
Ionis Pharmaceuticals Inc Aktie (IONS) Neueste Nachrichten
Ionis outlines >$2B peak sales target for olezarsen as new launches and pipeline catalysts drive 2026 outlook - MSN
IONS SEC FilingsIonis Pharmaceuticals 10-K, 10-Q, 8-K Forms - Stock Titan
Connor Clark & Lunn Investment Management Ltd. Raises Stake in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Atika Capital Management LLC Invests $1.41 Million in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Insider Sell: Brett Monia Sells 160,773 Shares of Ionis Pharmaceuticals Inc (IONS) - GuruFocus
Ionis Pharmaceuticals (NASDAQ:IONS) CEO Sells $9,525,584.00 in Stock - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) CEO Brett Monia Sells 34,103 Shares of Stock - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells $2,827,460.45 in Stock - MarketBeat
Ionis Pharmaceuticals Presents at Barclays Healthcare Conference - National Today
Ionis (NASDAQ: IONS) EVP sells 37,277 shares under 10b5-1 plan - Stock Titan
Biogen Presents Additional Salanersen Data Showing New Motor Milestones Achieved in Children with SMA Previously Treated with Gene Therapy - Biogen
Capital World Investors Has $832.32 Million Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharma director Diaz sells $4.35m in IONS stock By Investing.com - Investing.com Nigeria
Ionis pharma director Loscalzo sells $82k in shares - Investing.com Nigeria
Ionis pharma director Klein sells $1.7 million in IONS stock - Investing.com Nigeria
Ionis Pharmaceuticals at Leerink Global Healthcare: Strategic Moves in 2026 By Investing.com - Investing.com Canada
Ionis Pharmaceuticals Announces Board Changes: Parshall and Wender to Retire, Reikes Rejoins in 2026 - Minichart
Ionis announces changes to Board of Directors - pharmiweb.com
Ionis Pharmaceuticals Announces Board Retirements and New Appointment - TipRanks
Ionis Pharmaceuticals (NASDAQ: IONS) plans board refresh as Parshall, Wender retire and Reikes returns - Stock Titan
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Ionis Pharmaceuticals, Inc. $IONS Position Raised by Rhenman & Partners Asset Management AB - MarketBeat
GW&K Investment Management LLC Sells 184,823 Shares of Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
DCF Advisers LLC Has $7.09 Million Stock Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
August 21st Options Now Available For Ionis Pharmaceuticals (IONS) - Nasdaq
Ionis pharma director Loscalzo sells $82k in shares By Investing.com - Investing.com UK
Insider Sell: Joseph Loscalzo Sells Shares of Ionis Pharmaceuticals Inc (IONS) - GuruFocus
Insider Selling: Ionis Pharmaceuticals (NASDAQ:IONS) EVP Sells 20,106 Shares of Stock - MarketBeat
C Frank Bennett Sells 85,089 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock - MarketBeat
Allene Diaz Sells 54,878 Shares of Ionis Pharmaceuticals (NASDAQ:IONS) Stock - MarketBeat
Ionis Pharma director Diaz sells $4.35m in IONS stock - Investing.com South Africa
Ionis Pharma EVP Devers sells $1.59 million in IONS stock By Investing.com - Investing.com Canada
Ionis pharma director Klein sells $1.7 million in IONS stock By Investing.com - Investing.com Australia
ARK Investment Management LLC Decreases Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Amova Asset Management Americas Inc. Decreases Holdings in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Legato Capital Management LLC Takes Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
HC Wainwright Analysts Raise Earnings Estimates for IONS - MarketBeat
American Century Companies Inc. Grows Position in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Ionis Pharmaceuticals (IONS) Receives Price Target Raise to $104 by Leerink Partners | IONS Stock News - GuruFocus
Ionis Pharmaceuticals (NASDAQ:IONS) Price Target Raised to $104.00 at Leerink Partners - MarketBeat
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: A Biotech Powerhouse with 15.60% Upside Potential - DirectorsTalk Interviews
Rafferty Asset Management LLC Decreases Stake in Ionis Pharmaceuticals, Inc. $IONS - MarketBeat
Oligonucleotides Global Markets, 2022-2024 & 2025-2030, Profiles of Major PlayersAlnylam Pharmaceuticals, Biogen/Ionis Pharmaceuticals, Novartis, and Sarepta Therapeutics - Yahoo Finance
FDA Priority Review And 2026 Outlook Might Change The Case For Investing In Ionis (IONS) - Sahm
Ionis Pharmaceuticals, Inc. $IONS Shares Bought by Envestnet Asset Management Inc. - MarketBeat
Ionis Priority Review And DAWNZERA Data Reframe Rare Disease Growth Story - Yahoo Finance
Ionis FDA And Phase 3 Updates Reframe Rare Disease Valuation Story - simplywall.st
Ionis Pharmaceuticals CEO Teases Late-June Olezarsen Launch After FDA Priority Review Acceptance - Yahoo Finance
Olezarsen Priority Review and Expanding Rare Disease Franchise Could Be A Game Changer For Ionis (IONS) - Yahoo Finance
Ionis Pharmaceuticals, Inc. $IONS Shares Bought by Artisan Partners Limited Partnership - MarketBeat
Ionis Pharmaceuticals (NASDAQ:IONS) Downgraded by Wall Street Zen to Sell - MarketBeat
Ionis presents new data on hereditary angioedema drug at AAAAI - Investing.com Australia
Ionis Pharmaceuticals Earnings Call Highlights Surging Momentum - TipRanks
Ionis Pharmaceuticals (NASDAQ:IONS) Given New $100.00 Price Target at Piper Sandler - MarketBeat
Ionis Pharmaceuticals (IONS) Target Price Raised to $100 by Pipe - GuruFocus
Ionis presents new data on hereditary angioedema drug at AAAAI By Investing.com - Investing.com India
Analysts Have Conflicting Sentiments on These Healthcare Companies: Amarin (AMRN), Ionis Pharmaceuticals (IONS) and Repligen (RGEN) - The Globe and Mail
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):